NCT07002177 2026-01-07
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Forward Pharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT05563220 2026-01-06
ELEVATE
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06428396 2025-12-26
LITESPARK-029
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06680921 2025-09-22
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05594095 2024-10-04
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT05949541 2024-02-08
BCTOP-L-M01
Fudan University
Phase 2 Recruiting
NCT05954442 2024-01-16
BCTOP-T-M03
Fudan University
Phase 3 Recruiting
NCT05983107 2023-08-09
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting